Lingbo Zhang
CSHL Fellow
Cancer Center Member
Ph.D., Joint program of Massachusetts Institute of Technology and National University of Singapore, 2013
lbzhang@cshl.edu | (516) 367-5414
Proper balancing of self-renewal and differentiation in hematopoietic stem and progenitor cells is a central question in hematopoiesis. My laboratory investigates how growth signals including nervous system activity through the hematopoietic arc - hematopoarc we recently identified and nutrients such as vitamin pathway regulate this key process and aims to develop novel therapeutic strategies for hematologic diseases and malignancies.
Stem and progenitor cells of many adult lineages undergo self-renewal and differentiation, and growth signal and nutrient are two major regulators of this process. Exploiting mechanisms especially the role of growth signal and nutrient holds great promise for the development of regenerative medical strategies and the prevention of abnormal cell proliferation in cancer. The research of my laboratory centers on normal and malignant stem and progenitor cells in the hematopoietic system. We utilize functional genomics including chemical genomic and CRISPR/Cas9 functional genomic approaches to uncover novel regulators of growth signal and nutrient pathways. We recently identified the cholinergic receptor muscarinic 4 – CHRM4 as a novel regulator of early erythroid progenitor self-renewal and a therapeutic target for myelodysplastic syndrome. Our research uncovered the hematopoietic arc – hematopoarc, which is a novel nervous system activity based regulatory mechanism of hematopoietic stem and progenitor cell self-renewal and differentiation and a missing information without which we cannot target a group of devastating hematologic diseases. We also identified the vitamin B6 addiction as a selective and pharmacologically actionable target for acute myeloid leukemia. Through collaborations with medicinal chemists, we build pharmacological approaches to target these novel self-renewal regulators and metabolic vulnerabilities, and our findings will help to treat devastating hematologic diseases and malignancies, including myelodysplastic syndrome and leukemia.
2018 NIH Research Evaluation and Commercialization Hub Proof of Concept Award
2018 Edward P. Evans Foundation EvansMDS Young Investigator Award
2016 NIH Research Evaluation and Commercialization Hub Feasibility Award
2013 Chinese Government Award for Outstanding Self-finance Students Abroad
2008 Tsinghua University Outstanding Master Degree Thesis Award
Event: Canceled Cocktails & Chromosomes
February 18, 2020
As a precautionary measure to ensure the safety of our employees and visitors during the current COVID-19 outbreak, Cold Spring Harbor Laboratory (CSHL) is canceling and/or postponing events for public audiences.
Vitamin B6, leukemia’s deadly addiction
January 13, 2020
Acute Myeloid Leukemia is addicted to vitamin B6. Now that researchers know this, they can pursue new treatment options for the deadly blood cancer.
Vitamin B6, leukemia’s deadly addiction
January 13, 2020
Acute Myeloid Leukemia is addicted to vitamin B6. Now that researchers know this, they can pursue new treatment options for the deadly blood cancer.
Discovery could improve MDS cancer treatment
September 25, 2019
Researchers have discovered a promising new target for treating myelodysplastic syndrome (MDS), a common and lethal blood cancer.
From workshops to lab work—right next door
September 13, 2018
College student James Korossy’s journey from taking workshops at the DNA Learning Center to working at the bench in CSHL Fellow Lingbo Zhang’s lab.
Evans Foundation MDS Young Investigator Award to Lingbo Zhang
March 28, 2018
CSHL Fellow Lingbo Zhang received a Young Investigator Award from the Edward P. Evans Foundation.
New investigators join CSHL
November 14, 2014
An interview with newly hired investigators Scott Lyons and Lingbo Zhang.
Nature Chemical Biology – Hooked on vitamins
World Pharma News – Vitamin B6, leukemia’s deadly addiction
Medical News Today – Leukemia’s unexpected link to vitamin B-6
Drug Target Review – A novel target revealed for myelodysplastic syndrome
BioSpace – Newly discovered target overcomes drug resistance in lethal blood cancer
Bioengineer – Discovery could improve MDS cancer treatment
LI Bioscience Hub Backs 10 In New Funding Round
Scientists identify potential drug target for treatment-resistant anemias
Trivedi, Gaurang and Inoue, Daichi and Zhang, Lingbo (2021) Targeting low-risk myelodysplastic syndrome with novel therapeutic strategies. Trends in Molecular Medicine,
Chen, C. C. and Li, B. and Millman, S. E. and Chen, C. and Li, X. and Morris, J. P. Iv and Mayle, A. and Ho, Y. J. and Loizou, E. and Liu, H. and Qin, W. and Shah, H. and Violante, S. and Cross, J. R. and Lowe, S. W. and Zhang, L. (2020) Vitamin B6 Addiction in Acute Myeloid Leukemia. Cancer Cell, 37(1) pp. 71-84.
Trivedi, Gaurang and Inoue, Daichi and Chen, Cynthia and Bitner, Lillian and Chung, Young Rock and Taylor, Justin and Gönen, Mithat and Wess, Jürgen and Abdel-Wahab, Omar and Zhang, Lingbo (2019) Muscarinic acetylcholine receptor regulates self-renewal of early erythroid progenitors. Science Translational Medicine, 11(511)
Zhang, L. and Prak, L. and Rayon-Estrada, V. and Thiru, P. and Flygare, J. and Lim, B. and Lodish, H. F. (2013) ZFP36L2 is required for self-renewal of early burst-forming unit erythroid progenitors. Nature, 499(7456) pp. 92-6.
Hattangadi, S. M. and Wong, P. and Zhang, L. and Flygare, J. and Lodish, H. F. (2011) From stem cell to red cell: regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modifications. Blood, 118(24) pp. 6258-68.
Additional materials of the author atCSHL Institutional Repository